5-Iodo-indirubin-3'-monoxime

• CAT Number: I019230
• CAS Number: 331467-03-9
• Molecular Formula: C₁₆H₁₀IN₃O₂
• Molecular Weight: 403.17
• Purity: ≥95%
• Target: GSK-3; CDK
• IUPAC Name: 5-iodo-3-(3-nitroso-1H-indol-2-yl)-1H-indol-2-ol
• InChI: InChI=1S/C16H10IN3O2/c17-8-5-6-12-10(7-8)13(16(21)19-12)15-14(20-22)9-3-1-2-4-11(9)18-15/h1-7,18-19,21H
• InChIKey: WCCYEJYTLNWYCC-UHFFFAOYSA-N
• SMILES: C1=CC=C2C(=C1)C(=C(N2)C3=C(NC4=C3C=C(C=C4)I)O)N=O

5-Iodo-indirubin-3′-monoxime（Cat No.:I019230）is a potent derivative of indirubin, known for its ability to inhibit cyclin-dependent kinases (CDKs) and glycogen synthase kinase-3 (GSK-3). It effectively interferes with cell cycle progression and proliferation, making it useful in cancer research. Additionally, it modulates Wnt/β-catenin signaling by inhibiting GSK-3, contributing to its role in regulating cell fate, differentiation, and apoptosis. This compound has shown potential for inducing apoptosis in cancer cells and possesses anti-inflammatory properties, making it a valuable tool for studying cancer biology and other cellular processes involving CDKs and GSK-3.

Reference

[1]. Leclerc S, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer’s disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem. 2001 Jan 5;276(1):251-60.